|
Late Bloomer
Syantra emerged from nine years of stealth last week, announcing their liquid biopsy platform.
Nine years, eh? Guess the good news is they've already been through biotech puberty so should be ready to perform immediately.
Reset Expectations
Somewhat surprising to find a non-publicly traded psychedelic company, but not at all surprising they are courting investors. This one put a call to investors at the top of one page:
“Learn more about our science, our data, and investment potential”.
So, what do we learn from clicking that link?
"Not Found"
Too perfect.
CTRL Therapeutics --> cTRL Therapeutics
Man, we make one ctrl-alt-delete joke at their expense and CTRL Therapeutics has an identity crisis. They have now decapitalized the C.
Admittedly, it does look better. Glad to be forcing change, one sarcastic newsletter at a time.
Team Roast - Secret Agent
Very common for some team member pictures to be missing. Somewhat common for major jobs to be unfilled and noted on a Team page. Not common to be willing to state a person's qualifications, but nothing else.
Who is this mystery ASO expert with a PhD? And why did the company feel the need to publish that? Just omit it if you don't want to tell us about them.
That's like someone the other day told us they had information that may change our opinion on something, but they weren't going to share it. Then don't effing say you have that information!
Centivax
Pretty blunt slogan from Centivax: “Smash the Mutants”.
Is that a futuristic anti-alien propaganda campaign? Or perhaps Ninja-Turtle nemesis, Shredder, entered the witness protection program and is now going by the name Jacob?
One, Please
Found a few duplicates in our directory. Usually it happens because the names are slightly off. In one instance, we listed 60 Degrees Pharmaceuticals and also Sixty Degrees Pharma.
To find out which was correct, we Googled it and the search results said 60 Degrees Pharmaceuticals. Then we clicked on the website and the landing page said Sixty Degrees Pharma. Partway down that same page they went with 60° Pharmaceuticals.
Half shocked they didn’t drop a “6T” in place of 60 somewhere.
Unless they tell us otherwise, we are going with the ultralong form Sixty Degrees Pharmaceuticals just to spite them.
Claret Bioscience
This bunch chose the tagline "not your grandma's NGS libraries" and it's making us unsure whether they know anything about grandmas.
From our understanding, grandmas do not tend to have much love for any next-gen sequencing libraries. And probably not any first-gen sequencing libraries.
Hell, most pretty much never went to an actual library.
This same company is marketing two kits under the names "XACTLY" & "SRSLY", so they clearly hired the best 16-year-old marketing XPRT money could buy.
Branding Roast - Chordia
How can you tell when a company paid a lot of money to some branding consultants? When they painstakingly expound on what their company name means and what the colors in their logo represent.
Here Chordia Therapeutics is talking about musical notes and overlapping tones and drugs and generosity...it's all a bit much.
Then they get into the color scheme. Did y'all know Navy Peony is a dependable and anchoring shade? Did you even know it was a color? You probably did without knowing it, because most of us call it Navy Blue.
You must agree, Navy Peony sounds like a much, much better explanation of where that 50k marketing spend went.
Right To Bare Arms
This company’s team really runs the gamut of workplace attire – suit/tie, unbuttoned dress shirt with nothing beneath, sleeveless shirt, tuxedo.
At least the sleeveless getup was a woman which is generally accepted in the workplace. But if a man did it? Big nope. Just don't tell this guy on the scientific advisory board at EraCal.
And lest you think this is a one-off deal, there he is on his faculty page at Harvard with a shoulder peeking out to let us know he indeed has consistently atrocious style.
Imagine being successful enough to be on the Harvard faculty, and your claim to fame is being the sleeveless professor. #lifegoals
Did Ya Get That Funding?
Memo Therapeutics landed $25M this week. No word whether Inotec was involved in this round.
Do you think Memo celebrated with any pieces of Flare Therapeutics who had some good clinical study news come out the same week?
Damn it feels good to be a mid-tier biotech.
| 
